News and Announcements
OncoSil Medical Recruits Second Subject at Monash Health Melbourne for Global Pancreatic Clinical Study Programme
- Published May 11, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
OncoSil Medical Limited (ASX: OSL) a medical device company focused on localised treatments for patients with pancreatic and liver cancer, is pleased to announce that Monash Health has recruited the second subject for its global clinical study program in pancreatic cancer. The second subject has completed all baseline assessments, and will now commence one month of chemotherapy prior to implantation with the OncoSil™ device.
KEY TAKEAWAYS:
- Secondsubjectrecruited for global clinical study in pancreatic cancer by MonashHealth, Melbourne
- This subject is the second in a total of 20 subjects required to meet the Supplemental data request to secure CE Marking
- First subject implanted with the OncoSil™ device on April 24 at Monash Health, Melbourne
OncoSil Chief Medical Officer Dr Ashish Soman commented: “We are pleased with the recruitment efforts and engagement to date by MonashHealth as our lead Australian trial site, and continue to work closely with their team to progress additional patient recruitment for this important global study.”
OncoSil Medical is a medical device company seeking to advance radiation for cancer patients.